Live Breaking News & Updates on Brian deschuytner

Stay informed with the latest breaking news from Brian deschuytner on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Brian deschuytner and stay connected to the pulse of your community

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 […]

Blackrock , Nova-scotia , Canada , Montreal , Quebec , Switzerland , Swiss , Anna-protopapas , Robertw-baird , Brian-deschuytner , Jpmorgan-chase-co , Securities-exchange-commission

Mersana Therapeutics (NASDAQ:MRSN) Upgraded at JPMorgan Chase & Co.

Mersana Therapeutics (NASDAQ:MRSN) Upgraded at JPMorgan Chase & Co.
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Ohio , United-states , Robertw-baird , Brian-deschuytner , Anna-protopapas , Citigroup , Merck-kgaa , Merck-kga , Janssen-biotech-inc , Jpmorgan-chase-co , Nasdaq , Victory-capital-management-inc

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript February 28, 2024 Mersana Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all […]

Brian-deschuytner , Merck-kgaa , Johnson , Merck-kga , Chief-operating , Financial-officer , Commerce-companies , Mersana-therapeutics , Nc- , Arty-huber , Ason-fredette , Roduct-candidates

Truist Financial Upgrades Mersana Therapeutics (NASDAQ:MRSN) to Buy

Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) was upgraded by equities researchers at Truist Financial from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Benzinga reports. The firm presently has a $9.00 price objective on the stock. Truist Financial’s price target would indicate a potential upside of 85.57% […]

Hong-kong , Robertw-baird , Anna-protopapas , Brian-deschuytner , Merck-kga , Sphera-funds-management , Y-intercept-hong-kong-ltd , Citigroup , Janssen-biotech-inc , Mersana-therapeutics-inc , Asana-biosciences , Life-insurance-co

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript

Operator: Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all participants are in listen-only mode.

Barcelona , Comunidad-autonoma-de-cataluna , Spain , Marty-huber , Tara-bancroft , Dolasynthen-adcs , Jason-fredette , Ashiq-mubarack , Colleen-kusy , Brian-deschuytner , Martin-huber , Jonathan-chang

Mersana Therapeutics (NASDAQ:MRSN) Issues Quarterly Earnings Results

Mersana Therapeutics (NASDAQ:MRSN) Issues Quarterly Earnings Results
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada , Hong-kong , Brian-deschuytner , Anna-protopapas , Mersana-therapeutics-inc , Merck-kgaa , Royal-bank , Sei-investments-co , Securities-exchange-commission , Hong-kong-ltd , Merck-kga , Tower-research-capital

Mersana Therapeutics (MRSN) Scheduled to Post Earnings on Wednesday

Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) will be issuing its quarterly earnings data before the market opens on Wednesday, February 28th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Mersana Therapeutics Stock Performance Mersana Therapeutics stock traded up $0.17 during mid-day trading on Thursday, reaching $3.86. The company’s […]

Brian-deschuytner , Anna-protopapas , Asana-biosciences , Life-insurance-co , Citigroup , Panagora-asset-management-inc , Principal-financial-group-inc , Janssen-biotech-inc , Mersana-therapeutics-inc , Merck-kga , York-mellon-corp , Securities-exchange-commission

Mersana Therapeutics (MRSN) Scheduled to Post Earnings on Wednesday

Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) is set to release its earnings data before the market opens on Wednesday, February 28th. Analysts expect Mersana Therapeutics to post earnings of ($0.20) per share for the quarter. Mersana Therapeutics Stock Up 4.6 % Shares of Mersana Therapeutics stock traded up $0.17 during trading on Thursday, reaching […]

Anna-protopapas , Brian-deschuytner , Merck-kga , Principal-financial-group-inc , York-mellon-corp , Panagora-asset-management-inc , Asana-biosciences , Citigroup , Life-insurance-co , Janssen-biotech-inc , Mersana-therapeutics-inc , Merck-kgaa

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Update

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 6,650,000 shares, a decline of 10.0% from the January 15th total of 7,390,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the short-interest […]

Ohio , United-states , Anna-protopapas , Brian-deschuytner , Securities-exchange-commission , Citigroup , Mersana-therapeutics-company-profile , Mersana-therapeutics-inc , Barclays-plc , Vanguard-group-inc , Merck-kga , Merck-kgaa

Rhenman & Partners Asset Management AB Sells 378,300 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Rhenman & Partners Asset Management AB Sells 378,300 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Hong-kong , Anna-protopapas , Brian-deschuytner , Sphera-funds-management , Y-intercept-hong-kong-ltd , Nasdaq , Merck-kgaa , Asana-biosciences , Securities-exchange-commission , Mersana-therapeutics-inc , Life-insurance-co , Janssen-biotech-inc